Inactivation of DNA-mismatch repair underlies the genesis of microsatellite unstable (MSI) colon cancers. hPMS2 is one of several genes encoding components of the DNA-mismatch repair complex, and germline hPMS2 mutations have been found in a few kindreds with hereditary nonpolyposis colorectal carcinoma (HNPCC), in whom hereditary MSI colon cancers develop. However, mice bearing null hPMS2 genes do not develop colon cancers and hPMS2 mutations in sporadic human colon cancers have not been described. Here we report that in Vaco481 colon cancer the hPMS2 gene is inactivated by somatic mutations of both hPMS2 alleles. The cell line derived from this tumor is functionally de®cient in DNA mismatch repair. This de®ciency can be biochemically complemented by addition of a puri®ed hMLH1-hPMS2 (hMutLa) complex. The hPMS2 de®cient Vaco481 cancer cell line demonstrates microsatellite instability, an elevated HPRT gene mutation rate, and resistance to the cytotoxicity of the alkylator MNNG. We conclude that somatic inactivation of hPMS2 can play a role in development of sporadic MSI colon cancer expressing the full range of cancer phenotypes associated with inactivation of the mismatch repair system. Oncogene (2000) 19, 2249 ± 2256.
Introduction
The human mismatch repair system plays an important role in maintaining genomic integrity by removing replication errors from DNA in a strand-speci®c manner (Eshleman and Markowitz, 1996; Kolodner, 1996; Marra and Boland, 1995; Modrich, 1997) . Inactivation of this DNA repair system raises mutation rate by two to three orders of magnitude (Bhattacharyya et al., 1994; Eshleman et al., 1995) , and leads to the development of human cancers with microsatellite instability (Eshleman and Markowitz, 1996; Fishel and Kolodner, 1995; Kinzler and Vogelstein, 1996; Marra and Boland, 1995) . In particular, inactivation of DNA mismatch repair has been associated with human colon cancers displaying microsatellite instability [MSI] that arises in kindreds with the hereditary nonpolyposis colon cancer syndrome and additionally in 13% of sporadic nonfamilial colon cancers (Kinzler and Vogelstein, 1996) . Moreover, inactivation of mismatch repair in these cancers causes a mutator phenotype and a marked tolerance to the cytotoxicity of certain DNA methylating agents (Branch et al., 1993; Eshleman et al., 1995; Kat et al., 1993; Koi et al., 1994; Parsons et al., 1993) .
The human mismatch repair system involves interaction of several proteins including hMSH2, hMSH3, hMSH6, hMLH1, hPMS2, and possibly hPMS1 (Kolodner, 1996; Modrich and Lahue, 1996) . Of these, germ line mutations in hMSH2 and hMLH1 account for the great majority of HNPCC kindreds (Kinzler and Vogelstein, 1996; Peltomaki and Vasen, 1997) ; and somatic inactivation of hMLH1, hMSH2, hMSH3 and hMSH6 has been demonstrated in various sporadic colon cancers Malkhosyan et al., 1996; Risinger et al., 1996) .
The hPMS2 and hMLH1 proteins form the hMutLa heterodimer that functions as a component of the human MMR complex . Germ line mutations in hPMS2 have been described in two HNPCC kindreds Nicolaides et al., 1994) . However, hPMS2 de®cient gene knockout mice do not develop colon cancers (Baker et al., 1995; Prolla et al., 1998) , and the hPMS2 mutant HEC-1-A human endometrial cancer cell line has recently been determined to also bear mutant hMSH6 (Risinger et al., 1995; . Thus the extent to which hPMS2 mutation contributes to sporadic MSI colon cancer has remained unde®ned.
We have studied the Vaco481 colon cancer cell line established from a human MSI colon cancer which was previously determined to bear wild type hMSH2 and hMLH1 alleles . In this cell line both hPMS2 alleles are inactivated by mutations that are also present in the patient's tumor from which the cell line was established but are absent in this individual's germ line DNA. We ®nd that Vaco481 cells functionally lack DNA mismatch repair activity. This de®ciency can be biochemically complemented by addition of a puri®ed hMLH1-hPMS2 protein complex. The hPMS2 de®cient Vaco481 cancer cell line demonstrates microsatellite instability, an elevated HPRT gene mutation rate, and resistance to the cytotoxicity of the alkylator MNNG. We conclude that somatic inactivation of hPMS2 can have a role in development of sporadic MSI colon cancer expressing the full range of cancer phenotypes associated with inactivation of the DNA mismatch repair system.
Results

Vaco481 does not express hPMS2 protein
Mutations in the hPMS2 gene have been associated with inherited, non-polyposis colorectal carcinoma (HNPCC). However, the majority of HNPCC cases are due to underlying defects in either hMLH1 or hMSH2. In our colon cancer cell line bank, we screened numerous cell lines and noted that expression of hPMS2 protein was not detectable in the Vaco481 cell line. Figure 1a depicts a Western blot in which hPMS2 protein expression in Vaco481 is compared with expression of this protein in SW480 and HEC-1-A. SW480 is a non-MSI colon cancer cell line, which has no defect in MMR and serves as a positive control for expression of hPMS2 protein. HEC-1-A, which cannot synthesize either hPMS2 or hMSH6 protein, provides a negative control for hPMS2 expression in this experiment. As seen in HEC-1-A, the Western blot for Vaco481 is missing hPMS2 protein. Previously we have determined that in Vaco481 the sequences for both hMLH1 and hMSH2 are wild-type . Consistent with that data, good levels of hMLH1 and hMSH2 protein expression were demonstrated by Western analysis of Vaco481 (Figure 1a and c). Additionally, Western analysis also detected expression of hMSH6 protein in Vaco481.
hMLH1, but not hPMS2, is stable outside of the hMutLa heterodimeric complex hMLH1 and hPMS2 can associate both in vitro and in vivo to form a functional heterodimeric complex, hMutLa . However, as shown in Figure  1a , although neither Vaco481 nor HEC-1-A expresses hPMS2, levels of hMLH1 protein in these cells are not altered. Thus hMLH1 protein is apparently stable in the absence of hPMS2 and outside of the hMutLa complex. In contrast, we noted that hPMS2 and hMLH1 proteins were both absent in a number of colon cancer cell lines, such as HCT116, which are known to bear a primary defect in hMLH1 ( Figure  1b ). This suggested that hPMS2 protein is not stable in vivo in the absence of expression of wild-type hMLH1. This was directly demonstrated by the observation that both hMLH1 and hPMS2 proteins are absent in HCT116, but are both present in the HCT-CR3 cell line where reconstitution of wild-type hMLH1 protein expression is achieved by transfer of an exogenous human chromosome 3 (Figure 1b) . Thus, hPMS2 requires hMLH1 for intracellular stability, but hMLH1 does not exhibit a reciprocal relationship. The isolated absence of hPMS2 protein in Vaco481 was thus most consistent with a primary defect in the Vaco481 hPMS2 gene.
Vaco481 expresses only very low levels of hPMS2 mRNA
To assess expression of the hPMS2 transcript in Vaco481 we employed a RT ± PCR assay. As shown in Figure 2a , only low level expression of hPMS2 mRNA was detected in Vaco481. As expected from the (Figure 2b ) was followed throughout the cycles of PCR reactions as a control for mRNA expression. Analysis was carried out under PCR conditions where expression of hPMS2 was proportional to expression of actin mRNA in the SW480 control extracts and synthesis of the PCR products remained linear. The concentration of actin mRNA was similar in both SW480 and Vaco481 following 20 cycles of PCR whereas the hPMS2 mRNA expression was signi®cantly reduced in Vaco481 in comparison to SW480. Northern analysis also con®rmed that the Vaco481 cell line had signi®cantly less hPMS2 mRNA than SW480 cells.
hPMS2 is inactivated in patient colon cancer tissue and in the derived Vaco481 cell line through independent mutations of both alleles
To determine if the absence of hPMS2 protein and the reduced level of hPMS2 transcript re¯ected mutation of the hPMS2 gene, we sequenced full length 2.8 Kb hPMS2 cDNA products ampli®ed by RT ± PCR from the Vaco481 cell line. Sequencing of individual RT ± PCR ampli®ed clones demonstrated that Vaco481 expressed only mutant and no wild-type hPMS2 transcripts. Thirty per cent of the cDNA clones demonstrated a 4 base pair GATT deletion (nucleotides 2301 ± 2304) altering codons 767(CTG) and 768(ATT) located in exon 14 ( Figure 3a ). This frameshift mutation results in a premature stop during translation of hPMS2 mRNA. Forty per cent of the cDNA clones demonstrated a G to T mutation at codon 279 within exon 8 which converts GGA [Gly] to a premature TGA stop codon (Figure 3b ). Surprisingly, 30% of the clones demonstrated a third pattern in which the entire 100 base pairs of exon 8 were deleted from the hPMS2 transcript, and in which a newly created stop codon also results in a prematurely truncated hPMS2 protein product. Transcripts bearing the exon 14 frameshift were wild-type at exon 8; whereas transcripts that demonstrated either the exon 8 deletion or the premature stop codon at position 279 were wild-type at exon 14.
To exclude any artifact from RT ± PCR, we directly ampli®ed by PCR exons 8 and 14 from Vaco481 genomic DNA and sequenced the ampli®ed products. Both the exon 8 codon 279 GGA to TGA mutation, and the exon 14 codons 767 ± 768 GATT deletion were detected on sequencing the bulk PCR ampli®ed products. However, no abnormality was detected in the intron-exon junction sequences surrounding exon 8. It appears from this data that in Vaco481 hPMS2 is inactivated by independent mutations of both hPMS2 alleles. One of these mutations is a deletion of a GATT sequence located in exon 14 of one hPMS2 allele. The second of these mutations is a GGA to TGA mutation at codon 279 in exon 8. This latter mutation gives rise to two classes of aberrant transcripts. One class bears the codon 279 premature stop. The other class of transcripts eliminates the premature stop at codon 279 by aberrantly splicing out the entire exon 8, but still gives rise to a nonfunctional prematurely terminated hPMS2 protein. Such aberrant splicing around a stop codon mutation has previously been seen in other genes (Dietz et al., 1993) .
To demonstrate a role for hPMS2 mutations in colon cancer in the antecedent Vaco481 colon cancer, hPMS2 exon 8 and exon 14 were ampli®ed by PCR from genomic DNA of the patient's colon tumor. As in the hPMS2 de®cient tumor cell line, Vaco481, both mutations were again detected in PCR preparations ampli®ed from tumor DNA. The hPMS2 sequences were also examined in PCR products ampli®ed from the normal tissue portion of the resection specimen bearing the Vaco481 tumor. In the normal tissue hPMS2 was wild-type at exons 8 and 14. Thus the hPMS2 mutations in the Vaco481 colon cancer arose somatically and were selected for during tumorigenesis. Quantitative analysis by RT ± PCR of hPMS2 mRNA levels in Vaco481. A RT ± PCR method was used to analyse Vaco481 RNA extracts for the presence of hPMS2 mRNA. RNA samples extracted from SW480 and Vaco481 were ampli®ed. The expected position for hPMS2 PCR products is indicated on the gel (a). In order to assure that the PCR reaction yielded a reasonably quantitative estimate of relative mRNA levels in the SW480 versus the Vaco481 cell lines, the rate of production of actin mRNA (b) was followed throughout the cycles of the PCR reaction. In this manner, conditions for generation of hPMS2 cDNA were chosen in the middle range for ampli®cation of actin mRNA
Complementation of Vaco481 mismatch repair by hMutLa
As shown in Table 1 , nuclear extracts of Vaco481 cells do not process base-base or Insertion/Deletion [I/D] mismatches of one or two unpaired nucleotides to a signi®cant degree. Addition of puri®ed hMutLa (a complex of hMLH1 and hPMS2 proteins) to assays containing aliquots of Vaco481 extract restored mismatch repair to near normal levels for G´T mispairs and the single and dinucleotide I/D heteroduplexes. The level of restored activity upon addition of hMutLa to Vaco481 extracts varied slightly between extracts. Similar mismatch repair activity levels were observed upon addition of hMutLa to the hMLH1 7/7 extract from the mismatch repair de®cient cell line, H6. Although Vaco481 has a second mutation in hMSH3 and is, therefore, de®cient in hMutSb (a complex of hMSH2 and hMSH3 proteins), a defect in mismatch repair attributable to this mutation is not observable due to the presence of hMutSa (a complex between hMSH2 and hMSH6 proteins) in these extracts (see Table 1 , 3', CA, heteroduplex). This result is reminiscent of previous results in which I/D mismatch repair activity of hMutSb was demonstrated to overlap that of hMutSa (Genschel et al., 1998) . hMutSb may have distinct functions compared to hMutSa, but the nature of such functional dierences and the result of a lack of hMSH3 on this function are not presently known.
The conclusion that hMutSa is functional is supported by the Western assays, Figure 1 , demonstrating that both hMSH2 and hMSH6 as well as hMLH1 are present in Vaco481 at normal levels. While a mismatch repair assay is the only de®nitive way of determining the functional activity of mismatch repair proteins, we have found that presence of a mismatch repair protein by Western analysis correlates well with its functional activity in cell extracts (Littman, Drummond and Modrich, unpublished results) .
Therefore, since Vaco481 produces wild-type hMLH1, the functional de®ciencies in mismatch repair in this cell line can be concluded to arise from the hPMS2 defect, and the data further suggests both hMSH2 and hMSH6 encoded proteins are functional in this cell line.
hMSH3 mutation in Vaco481
A number of MSI cancers bearing mutations in hMLH1 or hMSH2 have been noted to additionally showing a G to T mutation at codon 279 within exon 8, which converts GGA (Gly) to a premature TGA stop codon. The hPMS2 transcripts bearing the exon 14 frameshift were wild-type at exon 8; whereas those harboring a mutation in exon 8 at position 279 were wild-type at exon 14 One hundred micrograms (100 mg) of hMLH1-de®cient H6 and hPMS2-de®cient Vaco481 nuclear cell extracts were tested for mismatch repair activity using 24 fmol of heteroduplex substrate in the absence (7) or presence (+) of 100 ng hMutLa, as described in Materials and methods. harbor frameshift mutations that inactivate hMSH3 (Malkhosyan et al., 1996; Risinger et al., 1996) . In these instances the hMSH3 mutations have been suggested to be targets of an initially induced MSI type mutator (Malkhosyan et al., 1996) . In Vaco481, Western analysis did not detect expression of hMSH3 protein. We therefore examined the state of the hMSH3 gene in Vaco481. PCR ampli®cation of the polyadenine tract within the hMSH3 coding region detected the presence of a one base insertion frameshift. This mutation occurred in the A(8) homopolymeric run found in exon 7 of hMSH3 at codons 372 ± 374. This hMSH3 mutation was also detected in the antecedent colon cancer from which Vaco481 was established, but was absent from corresponding normal tissue. The functional contribution of the hMSH3 defect to the Vaco481 MSI phenotype is uncertain. As noted above, extracts of Vaco481 when correctd for the defect in hPMS2 become fully pro®cient for repair of base-base mismatches and single and di-nucleotide mispairs; thus hMSH3 would appear to be dispensable for each of these activities. Moreover, recent characterization of a MSH3 knockout CHO derivative demonstrated no induction of microsatellite instability in the knockout cells (Hinz and Meuth, 1999) . We accordingly suggest that mutation of hPMS2 is the primary event in the genesis of Vaco481.
Vaco481 demonstrates a high mutation rate in the HPRT gene
We and others have shown that MSI colon cancer cell lines and other mismatch repair de®cient cell lines demonstrate a mutator phenotype in the form of a marked increase in mutation rates of expressed nonessential genes (Bhattacharyya et al., 1994; Eshleman et al., 1995) . To determine if hPMS2 de®ciency induces a comparable mutator phenotype we assayed the mutation rate of the HPRT gene in Vaco481 (Table 2 ). Consistent with our previous studies, the mutation rate in a control MMR repair pro®cient cell line, Vaco576, was below the limits of detection at less than 6610 78 mutants/generation. In contrast, the Vaco481 HPRT mutation rate was increased more than 160 fold to 10610 76 mutants/ generation, a mutation rate comparable to that measured in the hMLH1 de®cient HCT116 cell line. Thus hPMS2 inactivation confers a de®ciency of mismatch repair activity that is quantitatively equal to that conferred by hMLH1 de®ciency. We note that knockout of the hMSH3 gene in CHO cells does not increase HPRT mutation rates (Hinz and Meuth, 1999) , suggesting that the hMSH3 defect in Vaco481 is not likely to contribute signi®cantly to the observed results.
Vaco481 demonstrates resistance to the alkylator, MNNG
Mismatch repair de®cient cell lines harboring mutations in hMLH1, hMSH2 or hMSH6 display a high level of tolerance to the cytotoxic action of DNAalkylating agents (Branch et al., 1993; Kat et al., 1993; Koi et al., 1994; Umar et al., 1997) . In order to determine if an hPMS2 de®ciency exhibits this phenotype, Vaco481 was assayed for sensitivity to the cytotoxic eects of MNNG in comparison with HCT116 [MMR de®cient] and HCT116-CR3 [MMR pro®cient], which served as resistant and sensitive experimental controls, respectively. For these experiments, cells were treated with increasing concentrations of MNNG for 45 min at 378C, washed, and re-plated to assess colony-forming ability. Seven to ten days after treatment, the cells were ®xed and stained and the relative fraction of the surviving colonies was determined. As shown in Figure 4 , Vaco481 tolerates exposure to high concentrations of MNNG and exhibits a level of resistance that is indistinguishable from that observed in the HCT116 cell line. We note that knockout of the MSH3 gene does not alter MNNG sensitivity in CHO cells (Hinz and Meuth, 1999) , suggesting that alkylation tolerance in the Vaco481 cell line arises from the hPMS2 lesion.
Discussion
This study suggests that somatic mutation of hPMS2 can be a cause of sporadic non-familial human colorectal cancer with microsatellite instability. Moreover, such hPMS2 mutant cancers recapitulate the complete MSI phenotype (i.e. a mutator phenotype and resistance to DNA methylating agents) associated with cancers arising via inactivation of hMSH2 or hMLH1 (Bhattacharyya et al., 1994; Branch et al., 1995; Eshleman et al., 1995; Koi et al., 1994; Parsons et al., 1993) . The ®nding of somatic mutations in hPMS2 in the sporadic Vaco481 colon cancer provides strong Mutation of hPMS2 has not previously been demonstrated in a sporadic MSI colon cancer. Tumors from two HNPCC families were previously reported to bear germline defects in hPMS2 Nicolaides et al., 1994) , however cell lines from these tumors were not isolated. Further, mice that are homozygous de®cient for the PMS2 gene do not develop intestinal tumors despite in vivo demonstration of a 100-fold elevated frequency of +1 and 71 frameshift mutations (Baker et al., 1995; Prolla et al., 1998) . Indeed, the only previous well described human cancer cell line bearing a hPMS2 mutation is the endometrial cancer cell line, HEC-1-A, in which the hPMS2 mutation occurs concurrently with an inactivating hMSH6 mutation (Risinger et al., 1998) . Accordingly, one potential model to account for the paucity of hPMS2 mutations in human cancers would be that hPMS2 mutations require a collaborating second hit, such as an hMSH6 mutation, to fully inactivate the mismatch repair system. Our ®nding that in Vaco481 colon cancer the hMSH3 gene is mutated and lacks protein expression supports this model. However, several lines of evidence suggest that an hMSH3 de®ciency is much less potent than an hMSH6 de®ciency alone in perturbing mismatch repair function. Accordingly a secondary hMSH3 mutation in Vaco481 may have a lesser impact on the mismatch repair phenotype of Vaco481 than does the hMSH6 secondary mutation in HEC-1-A. First, as illustrated by the MT1 lymphoid and DLD1 colon cancer cell lines (Bhattacharyya et al., 1994; Drummond et al., 1995; Kat et al., 1993) , an isolated hMSH6 de®ciency is clearly sucient to induce a mutator phenotype. In contrast, an isolated hMSH3 de®ciency does not induce either microsatellite instability or resistance to DNA methylating agents (Hinz and Meuth, 1999) . Similarly, germline hMSH6 mutation can induce hereditary nonpolyposis colon cancer (Miyaki et al., 1997) ; whereas a germline mutation of hMSH3 has not been observed. Moreover, after genetic correction of the hPMS2 defect in HEC-1-A, the cells still demonstrate a partial repair defect in biochemical assays (Risinger et al., 1998) . In contrast, we observe that addition of puri®ed hMLH1-hPMS2 heterodimer to Vaco481 extracts restores repair pro®ciency. Lastly, in Vaco481 the hMSH3 mutation is due to a frameshift within a microsatellite-like hMSH3 coding region polyadenine repeat. Mutations within microsatellite and microsatellite-like repetitive sequences are a leitmotif of cells with established inactivation of mismatch repair. Accordingly, we favor the interpretation that microsatellite instability arose in Vaco481 via biallelic mutations in hPMS2, and that mutation of hMSH3 occurred as a subsequent and consequent event.
In summary, these studies of Vaco481 and its antecedents suggest that somatic mutation in hPMS2 may in some instances be the cause of sporadic MSI colon cancer characterized by microsatellite instability, a mutator phenotype, and resistance to alkylating agents. As the ®rst colon cancer cell line that bears an hPMS2 mutation, the Vaco481 cell line will serve as a valuable model for further studies of the role of hPMS2 in DNA repair and in MSI cancer.
Materials and methods
Cell lines and culture conditions
The human colon cancer cell line, Vaco481, was developed from the tumor of a female patient, 72 years of age suering from colon cancer as previously described . The cell line is grown in MEM medium supplemented with 2% fetal calf serum, insulin, selenium, hydrocortisone and transferrin.
The MMR-de®cient human colon cancer cell line, HCT116, and its reconstituted derivative, HCT116-CR3, were kindly provided by Dr Richard Boland. The HCT116 cell line harbors mutations in both alleles of the hMLH1 gene and is de®cient in hMLH1 activity. In the HCT116-CR3 cell line, MMR activity has been restored by introduction of a functional hMLH1 gene resulting on chromosome 3. HCT116 cells were cultured in MEM medium with 10% bovine calf serum. HCT116-CR3 cells were maintained in MEM medium with 10% bovine calf serum supplemented with 0.4 mg/ml G418 (GIBCO ± BRL) to ensure retention of chromosome 3.
The MMR-pro®cient human colon cancer cell line, SW480, and a MMR-de®cient human endometrial cancer cell line, HEC-1-A, were obtained from the American Tissue Culture Collection (ATCC). SW480 was cultured in 10% BCS-MEM. HEC-1-A was grown in McCoy's 5A medium supplemented with 10% BCS.
The MMR-pro®cient human colon cancer cell line Vaco576 (developed in Dr James Willson's laboratory) was maintained in MEM medium supplemented with 2% fetal calf serum, insulin, selenium, hydrocortisone and transferrin.
Visualization of hMLH1, hPMS2 and hMSH2 protein by Western analysis
Cells were treated in cell lysis buer composed of 50 mM Tris-HCl, pH 7.4, 1 mM EGTA, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl and freshly added proteinase inhibitors (1 mg/ml aprotinin, 1 mg/ml leupeptin and 5 m/ml PMSF). After lysis, the protein extracts were subjected to electrophoresis on a 7.5% SDS-polyacrylamide gel. The resolved proteins were then transferred to a PVDF Immobilon P membrane (Millipore). Anti-hMLH1 mouse monoclonal antibody (Pharmingen) at 2 mg/ml, anti-hPMS2 mouse monoclonal antibody (Pharmingen) at 2 mg/ml and anti-hMSH2 mouse monoclonal antibody (Oncogene Science) at 0.2 mg/ml were used to identify and quantify the expression of hMLH1 protein, hPMS2 protein and hMSH2 protein. Anti-actin mouse monoclonal antibody (Amersham) at 300 ng/ml was used to detect the endogenous actin protein, which served as an internal control. After incubation with horseradish peroxidasecoupled secondary antibody, reactive proteins were identi®ed and quanti®ed by autoradiography in the presence of an enhanced chemiluminescence reagent (ECL kit, Amersham).
Determination of hPMS2 mRNA expression: quantitative RT ± PCR Total RNA was isolated using the guanidine isothiocyanate/ cesium chloride method. One mg of total RNA was reverse transcribed using random hexanucleotides (Roche Molecular Biochemicals) and SuperScript II reverse transcriptase (GIBCO ± BRL) in a volume of 50 ml. After reverse transcription, 1 ml of cDNA was ampli®ed separately by a polymerase chain reaction (PCR) either for full-length hPMS2 or for b-actin using Expand High Fidelity Taq DNA polymerase (Roche Molecular Biochemicals). The primer set for hPMS2 was chosen from GenBank hPMS2 sequences U13696 and U14658 using MacVector 6.0 software. The primer set for b-actin was purchased from Clontech. The RT ± PCR products were analysed by electrophoresis on a 1% agarose gel, followed by ethidium bromide staining.
Sequencing of hPMS2 cDNA
The total RNA sample isolated from the Vaco481 cell line was reverse transcribed as described above. One ml of cDNA was ampli®ed by PCR to generate full length hPMS2 using Expand High Fidelity Taq DNA polymerase (Roche Molecular Biochemicals). RT ± PCR product was subcloned into pCR2.1-ToPo using the TOPO-TA cloning system (InVitrogen). Plasmid DNA was puri®ed (Qiagen miniprep kit) and subjected to ABI 377 automatic sequencing (Yale Sequencing Core Facility). The sequencing primers were selected from GenBank hPMS2 sequences U13696 and U14658 employing MacVector 6.0 software.
Isolation of genomic DNA from cell line, tumor tissue or from normal colon tissue Tumor tissue or normal colon tissue was frozen in liquid nitrogen and homogenized in a pulverizer. Genomic DNA from both the tissue and the Vaco481 cell line was obtained by lysing cells in Proteinase K buer (10 mM Tris, pH 7.4, 10 mM EDTA, 0.4% SDS, 150 mM NaCl and 100 mg/ml proteinase K), followed by a phenol:chloroform:isoamyl alcohol (25 : 24 : 1) extraction.
Sequencing of genomic hPMS2 DNA
Genomic DNA encoding either exon 8 and its¯anking region or exon 14 and its¯anking region were ampli®ed by PCR and subjected to cycle sequencing (GIBCO ± BRL kit). Genomic DNA encoding exon 14 was also cloned into TOPO-TA vector and plasmid DNA was puri®ed (Qiagen miniprep kit) and subjected to ABI 377 automatic sequencing (Yale Sequencing Core Facility). The primer sequences were selected from the published hPMS2 sequence employing MacVector 6.0 software.
HPRT mutation assay
Cultures were purged of pre-existing HPRT mutants by dilution. Speci®cally, 18 replicate subcultures were diluted to 100 cells per culture and each subculture was expanded to approximately 3610 6 cells. These cultures were then plated at 10 4 cells per well in 96 well plates in growth medium containing 1.5 mg/ml 6-thioguanine (6TG). HPRT mutants were identi®ed 1 month later by scoring for clonal survival using phase contrast microscopy. Cloning eciency (CE) was determined by seeding 1 ± 3 cells per well in 96 well plates in the presence of 1610 4 gamma irradiated (60 Gy 137 Cs) SW480 feeder cells. Methods for calculating CE, mutation frequency and mutation rate were described previously (Eshleman et al., 1995) .
MNNG toxicity assay
Cells were trypsinized, counted, resuspended at 10 6 cells/ml in MEM containing 10 mM O 6 -benzylguanine (O 6 BG) and incubated at 378C for 2 h to deplete endogenous O 6 -alkylguanidine DNA alkyltransferase (AGT). The cultures were then treated with dierent concentrations of MNNG (0 mM, 1.25 mM, 2.5 mM, and 5.0 mM) for 45 min. Cells were washed once, subjected to limited dilution, plated in 100 mm tissue culture plates and incubated in culture medium at 5% CO 2 for about 2 weeks. Surviving clones were stained with methylene blue and counted. Cloning eciency and drug toxicity responses were calculated.
Mismatch repair and complementation assays
Mismatch repair activity in cell free extracts was evaluated as described previously Parsons et al., 1993) . Brie¯y, mismatch repair assays were performed with 100 mg of nuclear extract, which was incubated with 24 fmol (100 ng in 10 ml) of f1-derived heteroduplex substrate for 15 min at 378C (Parsons et al., 1993; Holmes et al., 1990) . Complementation was performed by the addition of 100 ng of hMutLa, puri®ed from HeLa cells and the ®nal concentration of potassium chloride in the assay was adjusted to 100 mM, as described previously . The circular duplex substrates were prepared from f1MR1 (Parsons et al., 1993; Holmes et al., 1990) . The 5' heteroduplex substrates contain a nick 125 nucleotides 5' to the mispair (short path) and the 3' heteroduplex contains a single-strand break 181 nucleotides 3' to the mispair (short path) as previously described . For the / A \ heteroduplex I/D, the unpaired adenosine is located in a run of six adenosines in the continuous viral strand (Drummond et al., 1995) , whereas for the / CA \ heteroduplex, the I/D is in the complementary strand of f1MR (Parsons et al., 1993) . The base-base mispair G´T is located at position 5630 of the 6440 base pair heteroduplex with the G of the mispair located on the nicked strand (Holmes et al., 1990) . Reactions were terminated by addition of 30 ml of 25 mM EDTA/0.67% SDS/50 mg/ml proteinase K solution for 15 min at 378C. Reactions were then subject to phenol extraction followed by ethanol precipitation and restriction enzyme digestion. The extent of mismatch correction was determined by the production of hydrolytic products following cleavage by a speci®c restriction enzyme (located at the mismatch or I/D site) and a second restriction enzyme, Bsp106, as previously described (Holmes et al., 1990) . Restriction products were separated by gel electrophoresis in 1% agarose and quanti®ed by a cooled charge-coupled device imager (Photometrics) following staining with 1 mg/ml ethidium bromide as described . Values are expressed as femtomoles of repair products produced in 15 min with 100 mg of extract protein.
hMSH3 mutation assay
Genomic DNA encoding exon 7 of hMSH3, which encompasses the (A) 8 track in the hMSH3 gene and its anking region, was ampli®ed by PCR and subjected to electrophoresis on 6% denaturing polyacrylamide gel. The primer sequences are as follows according to Malkhosyan et al. (1996) : Forward primer: 5'-AGATGTGAATCCCC-TAATCAAGC-3'; Backward primer: 5'-ACTCCCA-CAATGCCAATAAAAAT-3'. Forward primer was 5'-end labeled with a-33 P by polynucleotide kinase. High ®delity DNA polymerase PWO was used in the PCR reaction. PCR was carried out for 30 cycles, each consisting of 958C for 45 min, 538C for 30 min and 728C for 30 min followed by a ®nal extension at 728C for 5 min. 
